The stock of Mettrum Health Corp (CVE:MT) hit a new 52-week high and has $13.43 target or 152.00% above today’s $5.33 share price. The 6 months bullish chart indicates low risk for the $295.40 million company. The 1-year high was reported on Nov, 11 by Barchart.com. If the $13.43 price target is reached, the company will be worth $449.01M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 1.43 million shares traded hands or 160.15% up from the average. Mettrum Health Corp (CVE:MT) has risen 6.00% since October 12, 2016 and is uptrending. It has underperformed by 0.15% the S&P500.
More notable recent Mettrum Health Corp (CVE:MT) news were published by: Investingnews.com which released: “Mettrum Health” on June 06, 2016, also Reuters.com with their article: “BRIEF-Mettrum Health Corp says all licenses at Bowmanville facilities rene…” published on February 05, 2015, Reuters.com published: “BRIEF-Mettrum Health Q1 loss per share $0.03” on November 16, 2014. More interesting news about Mettrum Health Corp (CVE:MT) were released by: Marketwired.com and their article: “Mettrum Health Corp. Responds to Health Canada’s Proposed Access to Cannabis …” published on August 11, 2016 as well as Marketwired.com‘s news article titled: “Mettrum Health Corp. Announces Full Exercise of Over-Allotment Option” with publication date: September 07, 2016.
Mettrum Health Corp. is a producer of medical cannabis. The company has a market cap of $295.40 million. The Firm is also a licensed producer and distributer of industrial cannabis (hemp) products, including Mettrum’s functional food line, Mettrum Originals. It currently has negative earnings. It has a production capacity of over 12,000 kilograms of medical cannabis per year.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.